Swiss Virtual Clinic uniquely designed for Cataract Surgery
If you or someone you know is dealing with cataract surgery, sorting through the sheer volume of information can be overwhelming. Reliable details aren’t always easy to find, which is exactly why the Swiss Virtual Clinic was created by Swiss Advanced Vision (SAV-IOL SA). This first-of-its-kind online platform offers tailored access for both patients and eyecare professionals, making it simpler than ever to access the right information in one place.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320758061/en/
Cataract surgery is one of the most common eye procedures, yet for many patients, it still feels like a mystery. The Swiss Virtual Clinic makes things clearer with an easy-to-use interface that explains the procedure, potential concerns, and what to expect - all for free on sav-iol.com.
For eyecare professionals, keeping up with the latest in cataract surgery can be a challenge. From available tools to technical queries, finding information takes time - time that could be better spent focusing on patients. The newly launched Swiss Virtual Clinic offers a dedicated section, packed with valuable resources to support their work. And the best part? It’s designed to be intuitive and regularly updated so professionals can find exactly what they need when they need it. Since this pro section contains specialized medical content, users will need to register to ensure that only experts in the field can engage with the materials.
This launch is a major evolution and reinforces SAV-IOL’s portfolio built on innovation, quality, and precision. “And it marks just the beginning. More features are already in the pipeline as we continue adapting to the evolving needs of ophthalmic surgeons and their patients,” says Alexandre Pascarella, CEO of Swiss Advanced Vision.
If you’re an eyecare professional looking to save time and streamline your practice, now’s the perfect moment to join the Swiss Virtual Clinic. Subscriptions are open on sav-iol.com! For those attending the APAO Congress this year, there’s an opportunity to experience exclusive insights firsthand. From 3rd to 6th April, Swiss Advanced Vision will be showcasing the latest innovation at its booth in New Delhi.
Since 2009, SAV-IOL develops and markets advanced EDOF IOLs globally. Its LUCIDIS and EDEN lenses, powered by Instant Focus technology, provide continuous vision from near to intermediate and far distances.
The Swiss Virtual Clinic opens the door to brand new tailored services accompanying surgeons and their medical teams as well as patients to approach cataract surgery in a truly disruptive way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320758061/en/
Contacts
Hülya AYDIN
Brand & Marketing Manager
hulya.aydin@sav-iol.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nederlandse Innovatie Maatschappij (NIM) Leads H2ESTIA Project: The Future of Emission-Free Cargo Transport27.3.2025 07:00:00 CET | Press Release
The maritime industry is taking a large step toward sustainability with the launch of the H2ESTIA Project, a groundbreaking initiative to develop the world’s first zero-emission general cargo ship powered by liquid hydrogen. Led by the Dutch Innovation Company (NIM – www.nim-bv.nl ) and supported by the Dutch Ministry of Infrastructure and Water Management, this initiative is a key pillar of the Maritime Masterplan, setting a new standard for decarbonizing European maritime logistics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326530510/en/ Concept design of the zero-emission hydrogen powered bulk carrier The project focuses on designing, constructing, and demonstrating a hydrogen-powered cargo vessel that will operate in the North Sea and beyond. Managed by Van Dam Shipping, the ship is designed to transport bulk goods, eliminating harmful emissions and redefining the future of sustainable shipping. At the heart of t
IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale27.3.2025 07:00:00 CET | Press Release
IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production will use IFF’s Designed Enzymatic Biomaterial™ (DEB) platform technology, integrated at the IFF biorefinery in Kotka, Finland. "Our partnership with Kemira has reached a significant milestone, enabling us to scale the production of groundbreaking biobased materials to meet the large and growing demand for high-performing and sustainable alternatives to fossil-derived polymers," said Erik Fyrwald, IFF CEO. "IFF’s DEB technology not only guarantees superior purity and consistency compared to traditional biopolymers but also en
Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis27.3.2025 07:00:00 CET | Press Release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health Canada to launch the Phase 2a INFLAM MOTION “Proof-of-Concept” study for 4P004 in patients with knee osteoarthritis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326675460/en/ Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Canada. It will enroll 129 patients to evaluate, for the first time, the efficacy of 4P004 in individuals with knee osteoarthritis. 4P004 is a GLP-1 analog, tailored for intra-articular use in knee osteoarthritis. It was developed to exploit the analgesic, anti-inflammatory, anti
Curatis: Sales growth of 30% in distribution - plus significant expansion of patient target group for lead project C-PTBE-0127.3.2025 07:00:00 CET | Press Release
Curatis Holding AG (SIX:CURN, ‘Curatis’) reports business revenues of CHF 6.9m for 2024, whereby Curatis AG is only included for 8 months. Curatis AG was able to increase sales in the distribution business by 30% per cent to CHF 9.5m in the full year 2024 compared to 2023. Further key statements: Curatis is increasing the estimate for the number of patients addressed in the lead project C-PTBE-01 by a factor of 20. The reason for this is that Curatis can apply for a biologics licence for C-PTBE-01, which grants 12 years of market protection in the USA. This suggests an expansion of the indications, namely from PTBE in diffuse midline glioma (DMG) in children to PTBE in other primary and metastatic brain tumours in children and adults. A meeting with the US Food and Drug Administration (FDA) to discuss a potential pivotal Phase III trial for C-PTBE-01 is in preparation and is targeted for Q2. The strong cash position of CHF 3m at the end of the year combined with the positive, growing c
Invivoscribe Announces Registration of the LeukoStrat ® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland27.3.2025 06:00:00 CET | Press Release
Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. The LeukoStrat CDx FLT3 Mutation Assay aids in the accurate detection of FLT3 mutations, empowering clinicians to make informed treatment decisions. This milestone ensures expanded accessibility of critical treatments to patients diagnosed with acute myeloid leukemia (AML). Regulatory compliance in the UK and Switzerland has been achieved through Invivoscribe’s UK Responsible Person (UKRP) and Swiss Authorized Representative (CH-REP), ensuring full adherence to national regulatory frameworks. Both the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, and Swissmedic in Switzerland—have officially registered this CDx assay. These agencies are responsible for ensuring product safety, efficacy, and compliance with post-market surveillance requirements. AML is an aggressive and ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom